Skip to main content

Advertisement

SpringerLink
Log in

Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Liver transplantation is the definitive treatment for patients with end-stage liver disease. Liver transplantation is also the optimal treatment for patients with hepatocellular carcinoma (HCC), especially in the setting of chronic liver disease. Unfortunately, due to the worldwide shortage of organs, this treatment is not available for all patients with HCC. Strict selection criteria have been developed in order to obtain optimal results. A surgical perspective of the preoperative selection, perioperative management, and postoperative care of patients is reviewed in depth and provides an overview for obtaining optimal long-term results from liver transplantation for HCC. With rigorous selection and patient management, excellent long-term outcomes can be obtained with liver transplantation for patients with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: Cancer J Clin. 2017;67:7–30.

    Google Scholar 

  2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.

    Article  CAS  PubMed  Google Scholar 

  3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.

    Article  CAS  PubMed  Google Scholar 

  4. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–823.

    Article  PubMed  Google Scholar 

  5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.

    Article  CAS  PubMed  Google Scholar 

  6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68:7–30.

    Google Scholar 

  7. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853.

    Article  PubMed  Google Scholar 

  8. Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–637.

    Article  PubMed  Google Scholar 

  9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.

    Article  CAS  PubMed  Google Scholar 

  10. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.

    Article  CAS  PubMed  Google Scholar 

  11. Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol. 2009;135:1403–1412.

    Article  PubMed  Google Scholar 

  12. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transplant. 2008;14:935–945.

    Article  Google Scholar 

  13. Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007;25:299–302.

    Article  Google Scholar 

  14. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transplant. 2008;14:1107–1115.

    Article  Google Scholar 

  15. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–1732.

    Article  CAS  PubMed  Google Scholar 

  16. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.

    Article  Google Scholar 

  17. Hsu CY, Liu PH, Lee YH, et al. Using serum alpha-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS ONE. 2015;10:e0118825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Grat M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and alpha-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014;38:2698–2707.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transplant. 2014;20:945–951.

    Article  Google Scholar 

  20. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987–999.

    CAS  PubMed  Google Scholar 

  21. Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416–427.

    Article  PubMed  Google Scholar 

  22. Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265:557–564.

    Article  PubMed  Google Scholar 

  23. Mehta N, Heimbach J, Harnois DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3:493–500.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transplant. 2007;13:543–551.

    Article  Google Scholar 

  25. DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166–172.

    Article  PubMed  Google Scholar 

  26. Sapisochin G, Goldaracena N, Laurence JM, et al. The extended toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64:2077.

    Article  PubMed  Google Scholar 

  27. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015;15:17–38.

    Article  PubMed  Google Scholar 

  28. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplant. 2002;8:873–883.

    Article  Google Scholar 

  29. Ishaque T, Massie AB, Bowring MG, et al. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. Am J Transplant. 2019;19:564–572.

    Article  PubMed  Google Scholar 

  30. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2014;20:937–944.

    Article  Google Scholar 

  31. Montalti R, Mimmo A, Rompianesi G, et al. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation. 2014;97:220–226.

    Article  PubMed  Google Scholar 

  32. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transplant. 2007;13:272–279.

    Article  Google Scholar 

  33. Pommergaard HC, Rostved AA, Adam R, et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European liver transplant registry. Transplant Int. 2018;31:531–539.

    Article  Google Scholar 

  34. Lee MW, Raman SS, Asvadi NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology. 2017;65:1979–1990.

    Article  CAS  PubMed  Google Scholar 

  35. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–1928.

    Article  CAS  PubMed  Google Scholar 

  36. Sandroussi C, Dawson LA, Lee M, et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transplant Int. 2010;23:299–306.

    Article  Google Scholar 

  37. Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92–99.

    Article  PubMed  Google Scholar 

  38. Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016;1:35–42.

    Article  PubMed  Google Scholar 

  39. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192–201.

    Article  PubMed  Google Scholar 

  40. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.

    Article  CAS  PubMed  Google Scholar 

  41. Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology. 2010;51:165–173.

    Article  CAS  PubMed  Google Scholar 

  42. Hoffmann K, Ganten T, Gotthardtp D, et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients—a prospective, randomized, double-blind, phase III trial. BMC Cancer. 2015;15:392.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90 ± sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61:309–317.

    Article  CAS  PubMed  Google Scholar 

  44. Sneiders D, Houwen T, Pengel LHM, Polak WG, Dor F, Hartog H. Systematic review and meta-analysis of posttransplant hepatic artery and biliary complications in patients treated with transarterial chemoembolization before liver transplantation. Transplantation. 2018;102:88–96.

    Article  PubMed  Google Scholar 

  45. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplant. 2010;16:262–278.

    Article  Google Scholar 

  46. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transplant. 2005;11:1505–1514.

    Article  Google Scholar 

  47. Mehta N, Guy J, Frenette CT, et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within milan criteria: a multicenter study. Clin Gastroenterol Hepatol. 2018;16:955–964.

    Article  PubMed  Google Scholar 

  48. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–1977.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250–1258.

    Article  PubMed  Google Scholar 

  50. Toso C, Meeberg G, Andres A, et al. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence—a retrospective study. Transplant Int. 2019;32:163–172.

    Article  CAS  Google Scholar 

  51. Man K, Ng KT, Lo CM, et al. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases–activation of cell invasion and migration pathways. Liver Transplant. 2007;13:1669–1677.

    Article  Google Scholar 

  52. Croome KP, Lee DD, Burns JM, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. Am J Transplant. 2015;15:2704–2711.

    Article  CAS  PubMed  Google Scholar 

  53. Khorsandi SE, Yip VS, Cortes M, et al. Does donation after cardiac death utilization adversely effect hepatocellular cancer survival? Transplantation. 2016;100:1916–1924.

    Article  PubMed  Google Scholar 

  54. Battula N, Reichman TW, Amiri Y, et al. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma. Liver Transplant. 2017;23:299–304.

    Article  Google Scholar 

  55. Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895–904.

    Article  CAS  PubMed  Google Scholar 

  56. Grat M, Kornasiewicz O, Lewandowski Z, et al. The impact of surgical technique on the results of liver transplantation in patients with hepatocellular carcinoma. Ann Transplant. 2013;18:448–459.

    Article  CAS  PubMed  Google Scholar 

  57. Mangus RS, Fridell JA, Vianna RM, Cooper AB, Jones DT, Tector AJ. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation. 2008;85:1496–1499.

    Article  PubMed  Google Scholar 

  58. Akbulut S, Kayaalp C, Yilmaz M, et al. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients. World J Gastroenterol. 2013;19:1625–1631.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Han S, Kim G, Ko JS, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. Ann Surg. 2016;264:339–343.

    Article  PubMed  Google Scholar 

  60. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1:CD005033.

    Google Scholar 

  61. Katz SC, Shia J, Liau KH, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249:617–623.

    Article  PubMed  Google Scholar 

  62. Liu B, Teng F, Fu H, et al. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol. 2015;15:138.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206–1213.

    Article  CAS  PubMed  Google Scholar 

  64. Kwon S, Jeon JS, Ahn C, Sung JS, Choi I. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression. Biochem Biophys Res Commun. 2016;479:74–79.

    Article  CAS  PubMed  Google Scholar 

  65. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:715–722.

    Article  CAS  PubMed  Google Scholar 

  66. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplant. 2004;10:1301–1311.

    Article  Google Scholar 

  67. Geissler EK, Schnitzbauer AA, Zulke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125.

    Article  CAS  PubMed  Google Scholar 

  68. Ferreiro AO, Vazquez-Millan MA, Lopez FS, Gutierrez MG, Diaz SP, Patino MJ. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc. 2014;46:3496–3501.

    Article  CAS  PubMed  Google Scholar 

  69. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354.

    Article  CAS  PubMed  Google Scholar 

  70. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge. Transplant Int. 2013;26:109–118.

    Article  Google Scholar 

  71. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transplant. 2004;10:534–540.

    Article  Google Scholar 

  72. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324–331.

    Article  CAS  PubMed  Google Scholar 

  73. Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transplant. 2017;23:440–447.

    Article  Google Scholar 

  74. Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large euro-american series. Ann Surg Oncol. 2015;22:2286–2294.

    Article  CAS  PubMed  Google Scholar 

  75. Toso C, Cader S, Mentha-Dugerdil A, et al. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci. 2013;20:342–347.

    Article  PubMed  Google Scholar 

  76. Valdivieso A, Bustamante J, Gastaca M, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2010;42:660–662.

    Article  CAS  PubMed  Google Scholar 

  77. Kim R, El-Gazzaz G, Tan A, et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology. 2010;79:62–66.

    Article  CAS  PubMed  Google Scholar 

  78. Martin RC 2nd, Bruenderman E, Cohn A, et al. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: observations from a US regional analysis of the GIDEON registry. Am J Surg. 2017;213:688–695.

    Article  PubMed  Google Scholar 

  79. de’Angelis N, Landi F, Nencioni M, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Prog Transplant. 2016;26:348–355.

    Article  PubMed  Google Scholar 

  80. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.

    Article  CAS  PubMed  Google Scholar 

  81. Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer. 2017;64:e26682.

    Article  CAS  Google Scholar 

  82. Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct. 2018;4:e376.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Transplant Surgery, Department of Surgery, Virginia Commonwealth University, PO Box 980057, Richmond, VA, 23298-0057, USA

    Trevor W. Reichman & Chandra S. Bhati

  2. Division of Transplantation and Hepatobiliary Surgery, University of Florida, Gainesville, FL, USA

    Narendra R. Battula

Authors
  1. Trevor W. Reichman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chandra S. Bhati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narendra R. Battula
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor W. Reichman.

Ethics declarations

Conflict of interest

The authors of this manuscript have no conflicts of interest related to this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reichman, T.W., Bhati, C.S. & Battula, N.R. Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer. Dig Dis Sci 64, 976–984 (2019). https://doi.org/10.1007/s10620-019-05550-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05550-5

Keywords

Search

Navigation